Casirivimab/Imdevimab - An Indian Real World Experience : Review Dr. Kamal Kant Kohli10 Jun 2022 11:49 AM ISTThe antibody cocktail (Casirivimab and Imdevimab) has been approved in India for the treatment of mild to moderate COVID-19 in adolescents and adults...
Novel therapies in managing Allergic rhinitis: How far have we come? Dr. Kamal Kant Kohli8 Jun 2022 12:45 PM ISTAllergic rhinitis(AR) is a common respiratory condition affecting 40 % of the worldwide population. Due to its shared pathophysiology with...
Understanding the scope of Faropenem in Lower Respiratory Tract Infections(LRTIs) Dr. Kamal Kant Kohli1 Jun 2022 11:03 AM ISTLower Respiratory Infections(LRIs): Complexities in the Indian ContextIn India, the burden of lower respiratory tract infections (LRTIs) is...
Air pollution and allergic rhinitis: Understanding the invisible, yet the inevitable connection Dr. Kamal Kant Kohli19 May 2022 12:54 PM ISTThe spiking frequency of allergic respiratory illness over the last several decades, and the increasing rate of air pollution owing to urbanization,...
Review: Efficacy of Antiviral Agents Against Omicron Subvariant BA.2 Dr. Kamal Kant Kohli16 May 2022 11:45 AM ISTThe omicron (B.1.1.529) variant of SARS-CoV-2, has spread rapidly around the world and has already become the predominant variant circulating in many...
Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin? Dr.Pankaj P. Changedia14 May 2022 12:30 PM ISTEver since the introduction of antimicrobial agents, there has been an association between antibiotic use and the development of antimicrobial...
Analyzing the efficacy and safety of leukotriene receptor antagonists in the management of allergic rhinitis Dr. Kamal Kant Kohli29 April 2022 12:00 PM ISTAllergic Rhinitis (AR) is an inflammatory illness of the upper respiratory tract, with sneezing, itching, nasal congestion, and rhinorrhea as the most...
Respiratory Allergic Affections: Management in India and Therapeutic Effect of Montelukast Dr. Kamal Kant Kohli22 April 2022 10:00 AM ISTAllergic diseases have turned into a major health concern around the world, with India being no exemption. Purportedly, over 25% of the total...
Review: Casirivimab-Imdevimab antibody Cocktail in Patients Amidst and Post COVID-19 Treatment Dr. Kamal Kant Kohli28 March 2022 12:15 PM ISTCasirivimab and Imdevimab are two IgG1 anti-SARS-CoV-2 monoclonal antibodies, given emergency use authorization by the US FDA, European Medical...
Decoding REGEN-COV2 for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients Dr. Kamal Kant Kohli17 March 2022 11:45 AM ISTKidney transplant recipients are an immunocompromised population, with comorbid conditions such as obesity, diabetes, and coronary artery disease,...
Analyzing Proton pump inhibitor (PPI) induced dysbiosis and growing role of probiotics: Review Dr Mitul Prakashbhai Barot14 March 2022 11:45 AM ISTComprising a diverse plethora of bacterial species, the human intestinal microecology is considered to be a complex community (1). Sudden disruption...
Casirivimab and imdevimab in patients admitted to hospital with COVID-19: RECOVERY Trial Dr. Kamal Kant Kohli9 March 2022 5:19 PM ISTCasirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor-binding domain of the SARS-CoV-2...
